Review of NICE Technology Appraisal Guidance No.288; Dapagliflozin for the treatment of type 2 diabetes
Proposal to partially update the existing guidance
The consideration of a review of TA288; Dapagliflozin for the treatment of type 2 diabetes was deferred in January 2015.
In TA288, dapagliflozin triple therapy in combination with metformin and a sulfonylurea is currently only recommended for treating type 2 diabetes in the context of ongoing clinical trials.
Since TA288 was published, new evidence has become available for this indication. It is therefore appropriate to allow the Appraisal Committee the chance to review the use of dapagliflozin as a triple therapy treatment in combination with metformin and a sulfonylurea in light of this new evidence.
Consequently, we propose that a partial update of TA288 should be undertaken, focusing on recommendation 1.3 of the existing guidance. This recommendation should be updated via the single technology appraisal (STA) process.
In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators to inform us of any evidence which will help us decide the best way to update this guidance. Please see appendix A for a full list of the organisations we have contacted.
The Institute is also developing a clinical guideline for type 2 diabetes, which currently has draft recommendations out for consultation with stakeholders. There is no evidence available at this time to suggest that the other recommendations made in TA288 require an update at this time, but recommendation 1.1 refers to CG87, which is currently being updated in the ongoing clinical guideline.
As a result, the remaining recommendations in TA288 will need to be considered for review separately once the new clinical guideline is published. This will be subject to a separate consultation.
This page was last updated: 26 February 2016